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Future of Research into D-Cycloserine and Cue
Exposure Therapy for Addiction
To the Editor:
C ue-drug memories are remarkably persistent, precipitatingrelapse after years of abstinence. Cue-exposure therapy(CET) attempts to suppress these memories but has had only
modest success clinically (1). The cognitive enhancer D-cycloserine
(DCS) might improve CET efficacy through improved contextual
generalisation and prolonging of therapeutic effects.
The recent review by Myers and Carlezon (2) of this approach
shows DCS-enhanced extinction (DCS/CET) is often efficacious in
preclinical but not clinical studies. They highlight important limita-
tions of extant clinical studies to account for this disparity and
forward methods for maximizing the probability of finding a posi-
tive DCS/CET effect through constraining experimental variables to
increase sensitivity to subtle drug effects.
Although we concur with some of their recommendations, we
believe interventions for preventing relapse should address the
following clinical utility criteria: 1) large, reproducible effects on
reducing relapse rates, 2) long-lasting efficacy, 3) contextual invari-
ance, 4) feasible clinical implementation (insensitivity to slight vari-
ations in procedure), 5) cost- and time-effectiveness. We believe
that some of their recommendations are misaligned with these
criteria and may therefore not expedite the development of effica-
cious antirelapse treatments.
The recommendation that researchers design studies to “to
maximize the probability of detecting a DCS effect” suggests that
previous research was insufficiently sensitive to observe subtle DCS
effects. We feel that, given the number and sample sizes of extant
clinical studies (an additional three have been published since their
review showing null [3,4] or detrimental [5] DCS effects), such a type
II error rate would suggest a small effect and therefore a very limited
role in DCS/CET in addiction treatment. Notably, the opposite argu-
ment is not engaged (that some positive findings constitute type I
errors).
Myers and Carlezon suggest minimizing type II error in DCS/CET
studies with “sufficiently large sample size  consistent data; CRs
[conditioned responses] to drug cues in all participants obtained if
necessary through exclusion of nonresponders robust CR and
slow extinction to avoid floor effects.” Ours (6,7) and recent (35)
studies were well powered to detect medium/large DCS effects
(criterion 1). Furthermore, aberrant mnemonic processes in addicts
are inherently variable. By constraining variation in participant
characteristics, we create a highly artificial experimental situation
with very limited generalizability/validity for treatment applica-
tions (criterion 4).
If very large samples or minutely controlled experimental vari-
ables are required to observe DCS/CET effects, we doubt its promise
in effecting meaningful improvements in addicts’ prognoses. Clin-
ical intervention tests should be designed to objectively appraise
the impact on critical outcome variables (i.e., reduction in relapse
rates or craving). The suggestion that “response measures in clinical
studies should be chosen carefully so as not to overlook potentially
subtle behavioral effects  cue-elicited CRs such as autonomic reac-
tivity, craving, and withdrawal might be most appropriate” ab-
stracts away from the vital outcome measures for addiction treat-
ments (the relationship between these variables and relapse is
unclear). By selecting narrow, conceptually problematic response
variables to observe subtle behavioural effects, we lose sight of the
ultimate goal of this research. i
0006-3223Given the complex pharmacology of DCS, it is premature to
ssume a definitive dose-response relationship in humans. Studies
ave therefore largely used doses effective in anxiety disorders,
dministered so that peak plasma levels align with the acquisition
nd consolidation of CET (5,6). Recently null effects have been
ound across a wide range of doses (37) and the suggestion (2)
hat 125250 mg doses are too high runs contrary to positive
ndings with equivalent (15/30 mg/kg) (8) doses in rats and metare-
ression of dose-response (9) in anxiety studies. Excluding partici-
ants because of comorbid antidepressant use is restrictive in clin-
cal populations, as addiction and depression often co-occur. We
gree that lack of participant supervision posttest (while DCS is
ctive) is a major problem in clinical DCS/CET studies. However,
xtending inpatient treatment sessions by several hours to control
his may constitute false economy (criterion 5), given the likely
ubtle beneficial DCS effects.
Clinical DCS/CET studies are influenced by preclinical addiction
odels and successful DCS/CET for anxiety. A disconnect exists
etween memory processes in anxiety and addiction; the latter is
ore complex (2), involving changes in N-methyl D-aspartate re-
eptor subunit composition, particularly in alcoholism. The dispar-
ty between anxiety and addiction findings may be due to the basis
n distinct neurochemical and motivational memory processes in
umans. The incentive to maintain responding inculcated during
ET is very different for the two disorders: successful treatment for
nxiety results in the removal of an aversive outcome, whereas
uccessful treatment for addiction results in the prevention of re-
arding outcome, possibly explaining low transference of effects
eri- to posttreatment in the latter. Drug memories may also be
lder and more habitual than those in anxiety disorders. A 40-a-day
moker will experience 14,600 reinforcer exposures per year, per-
aps explaining why cue-drug memories are harder to ameliorate
han cue-fear memories in anxiety. Similarly, preclinical addiction
odels use abbreviated learning compared with human addicts.
emory strength and age, rather than lack of test sensitivity, might
est explain the disparate DCS/CET findings in rats, anxiety, and
ddiction. Many more CET sessions may therefore be needed to
how DCS effects in humans; it is possible that inhibitory learning
uring CET must become as well learned and habitual as cue-drug
emory to compete for expression. If so, DCS/CET would not meet
riterion 5.
More fundamentally, DCS/CET may lack efficacy due to not
argeting prepotent cue-drug memories. CET does not affect
hese memories but creates new inhibitory traces in a specific,
ovel, and often cue-impoverished context (the laboratory). Un-
ess DCS/CET can be shown to have permanent and context-
nvariant (criteria 2 and 3) effects in potentiating CET-based
xtinction traces to consistently win out over prepotent traces, it
ill likely not reduce relapse rates. At the very least, researchers
hould consider conducting DCS/CET in realistic drug-taking
nvironment to address problems with contextual modulation
f cue-reactivity (10).
We feel more promising treatment approaches come from re-
ent research into memory reconsolidation (11). Blocking reconsoli-
ation of reactivated cue-drug memories could potentially degrade
r abolish cue-drug memories, a more parsimonious and poten-
ially permanent solution than temporary suppression with com-
eting traces, however enhanced by drugs. Although we encour-
ge further research into DCS/CET, we ask that it not lose sight of
he ultimate goal of this endeavour in the pursuit of positive exper-
mental effects.
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